Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Not applicable Interventional

Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)

NCT02782442
View directory record Official record
Conditions
Treatment, Active Control, Schizophrenia, Psychosis, Schizoaffective Disorder, Psychotic Depression, Psychotic Mood Disorders, Psychotic Disorders, Psychotic Episode, Cognitive Impairment
Interventions
Structured Cognitive Training & PRIME, Computer Games Control & PRIME
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039
View directory record Official record
Conditions
Glioblastoma
Interventions
INCMGA00012, INCAGN01876, SRS, Brain surgery
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

NCT07225036
View directory record Official record
Conditions
Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer, Melanoma, Liver Metastases
Interventions
LD-LRT
Radiation
Lead sponsor
Jordan Kharofa
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Cortical Priming to Optimize Gait Rehabilitation in Stroke: a Renewal

NCT04477330
View directory record Official record
Conditions
Stroke
Interventions
Transcranial direct current stimulation (tDCS), Ankle motor training, High intensity interval speed based treadmill training (HIISTT)
Other · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Balance for Older Adults: Disseminating Tai Chi Fundamentals Through Community Organizations

NCT04447001
View directory record Official record
Conditions
Older Aged Adults; Balance
Interventions
Tai-chi prime (TCP)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
La Crosse, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Priming Expectations and Motor Learning With tDCS

NCT06039605
View directory record Official record
Conditions
Expectations, Motor Learning
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

NCT01044095
View directory record Official record
Conditions
Influenza
Interventions
FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
Biological
Lead sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Government
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing a Clinical Outcome Assessment for Opioid Craving

NCT05109429
View directory record Official record
Conditions
Opioid Craving, Opioid Use Disorder, Measure Development
Interventions
Neutral Cue-induced Craving, Visual Opioid Cue-induced Craving, Visual and Tactile Opioid Cue-induced Craving
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
Biological · Drug
Lead sponsor
Nouscom SRL
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

NCT00124124
View directory record Official record
Conditions
Melanoma
Interventions
KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide
Drug
Lead sponsor
Dr. Nina Bhardwaj
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Tdcs And cogNitive traininG cOmbined for AUD (TANGO)

NCT05062369
View directory record Official record
Conditions
Alcohol Use Disorder, Addiction
Interventions
TaskFlow Transcranial Electrical Stimulation device, Executive Function Focused Cognitive Training
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 3 Interventional

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

NCT00002942
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous bone marrow transplantation, peripheral blood stem cell transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine
Biological
Lead sponsor
University of Maryland Greenebaum Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

NCT06458439
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 24, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

NCT00503880
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 24, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

NCT07113041
View directory record Official record
Conditions
Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions
Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Priming Immunotherapy in Advanced Disease With Radiation

NCT03313804
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Immune checkpoint inhibitor, Radiation Therapy
Drug · Radiation
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 24, 2026, 7:53 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Internalized Stress in Relation to Alcohol Consumption

NCT06091189
View directory record Official record
Conditions
Stress, Physiological, Ethanol Intoxication, Distress, Emotional
Interventions
Relevant Trier Social Stressor Test (TSST), Ethanol, Placebo Trier Social Stressor Test (TSST), Placebo Beverage, Irrelevant Trier Social Stressor Test (TSST)
Behavioral · Drug
Lead sponsor
Texas Tech University
Other
Eligibility
21 Years to 29 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Protein and Energy Metabolism in Pediatric Crohn's Disease

NCT00583232
View directory record Official record
Conditions
Crohn's Disease, Protein Metabolism, Energy Metabolism
Interventions
Stable isotope infusions
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 24, 2026, 7:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

NCT05828095
View directory record Official record
Conditions
HIV-1-infection
Interventions
INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 24, 2026, 7:53 PM EDT